A resident of the Technopolis Moscow special economic zone, Akrus Biomed, is the first in Russia to begin producing samples of cell-based drugs for clinical trials.
The developments are aimed at treating critical burns, spinal injuries, joint injuries, and other severe conditions. Production is organized according to the international GMP standard, which guarantees compliance with the highest quality requirements.
The company's capacity allows it to produce up to 70,000 units of products per year, including biological and dermal skin equivalents, created in collaboration with the Institute of Developmental Biology of the Russian Academy of Sciences. Investments in the project exceeded 470 million rubles. Clinical trials of three drugs have already been launched, which will be the first regenerative medicine products of this type in the country.
The plans include the development of drugs for rehabilitation after heart attacks, strokes, chemotherapy, as well as means for prolonging active longevity.
Read more on the topic:
TPU scientists have developed innovative scaffolds for bone tissue regeneration
Scientists from Russia and South Africa will develop regenerative technologies
